

Issue Date: 18 August 2014

Closing Date: 12th September 2014, 5:00 pm CET time

Subject: **NOTICE NO. 1 TO REQUEST FOR PROPOSAL (RFP)**
TGF 014-040

Notice Number One to the Global Fund Request for Proposal TGF 14-040, issued 25 July 2014 (the “**RFP**”) is as follows:

1. Notice number 1: Country Specific Costs

The Global Fund previously indicated in schedule B1 posted on the Global Fund’s website on 25 July 2014, that country specific costs would be limited to product or packaging customisation. Should the bidder wish to make a submission on any other country specific costs, these should be submitted by describing them in the “Additional notes” section on all of the applicable “Country Specific” pages of schedule B1.

2. Notice number 1: Revised forecast volumes

The Global Fund previously indicated forecast volumes in schedule F of the RFP posted on the Global Fund’s website on 25 July 2014 in the section “2015 and 2016 Volume Forecast by Product”. Please note the following adjustments:

ARVs presented in the same order as in Schedule F of the RFP	Pack size for forecast	12 month base estimates for 2015 (and subsequent 12 month periods)	
		Quantity previously posted on the Global Fund’s website in schedule F on 25 July 2014	Adjusted quantity
Atazanavir 300 mg Capsule	30	60,000	No forecast provided
Ritonavir 100 mg Tablet	30	100,000	10,000
Abacavir + Lamivudine 600 mg + 300 mg Tablet	30	400,000	200,000
Atazanavir 150 mg Capsule	60	20,000	No forecast provided
Atazanavir 200 mg Capsule	60	30,000	No forecast provided
Lopinavir+ Ritonavir 200 mg + 50 mg Tablet	120	2,000,000	1,000,000
Lopinavir+ Ritonavir 100 mg + 25 mg Tablet	120	250,000	150,000

3. Notice number 1: PSA Terms and Conditions

Section 5.6 (d), Schedule F (PSA Terms and Conditions) of the Supplier Framework Agreement forms indicates a period of “thirty (45) days”. This should read as follows (see underscored): “thirty (30) days”.
